Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 27 of 109, showing 5 Applications out of 543 total, starting on record 131, ending on 135

# Protocol No Study Title Investigator(s) & Site(s)

131.

ECCT/24/08/04   WHO A66045
    Heat-stable carbetocin for the treatment of postpartum haemorrhage: a phase III, randomized, double-blind, active controlled, multicountry, multicentre, non-inferiority trial   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Machakos county hospital (Machakos county)
2. Pumwani maternity hospital (Nairobi City county)
3. Kiambu level 5 hospital (Kiambu county)
 
View

132.

ECCT/22/11/02   UNCPM 22120 5-FU Study
    UNCPM  22120: Safety of adjuvant, self-administered intravaginal 5-fluorouracil (5-FU) cream following cervical intraepithelial neoplasia grade 2 and 3 (CIN2/3) treatment among HIV-positive women in Kenya: A pilot study   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
2. Chemtai Mungo
Site(s) in Kenya
Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH)
 
View

133.

ECCT/23/03/01   Micronutrient supplementation
    Optimizing nutrient supplementation among pregnant and reproductive age women in Kenya (Virutubisho)   
Principal Investigator(s)
1. DR. Martha Kaeni Mwangome
Site(s) in Kenya
KILIFI
 
View

134.

ECCT/25/03/04   Ndovu RCT
    Investigating the optimal management of dolutegravir resistance: an open-label randomised controlled trial of maintaining dolutegravir or switch to ritonavir-boosted darunavir   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kenyatta National Hospital (KNH) (Nairobi City county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
3. Bomu Hospital (Mombasa county)
 
View

135.

ECCT/21/06/05   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of ageand older   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR-PHRD THIKA PROJECT
 
View